CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy by Khanna, N et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
CD4+ T cell count recovery in HIV type 1-infected patients is
independent of class of antiretroviral therapy
Khanna, N; Opravil, M; Furrer, H; Cavassini, M ; Vernazza, P; Bernasconi, E; Weber,
R; Hirschel, B; Battegay, M; Kaufmann, G R
Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M;
Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of
antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Clinical Infectious Diseases 2008, 47(8):1093-1101.
Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M;
Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of
antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Clinical Infectious Diseases 2008, 47(8):1093-1101.
CD4+ T cell count recovery in HIV type 1-infected patients is
independent of class of antiretroviral therapy
Abstract
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1)
infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase
inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on
immunological recovery remains uncertain. METHODS: During January 1996 through May 2007, all
patients in the Swiss HIV Cohort were included if they received the first combination antiretroviral
therapy (cART) and had known baseline CD4(+) T cell counts and HIV-1 RNA values ([Formula: see
text]). The mean (+/-SD) duration of follow-up was [Formula: see text] months. The follow-up time was
limited to the duration of the first cART. CD4(+) T cell recovery was analyzed in 3 different treatment
groups: nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4(+) T cell
count in the 3 treatment groups after the initiation of cART. RESULTS: Two thousand five hundred
ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%) initiated an NNRTI regimen,
and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4(+) T cell count increases at 48 months
were as follows: in the nonboosted-PI group, from 210 to 520 cells/muL; in the NNRTI group, from 220
to 475 cells/muL; and in the boosted-PI group, from 168 to 511 cells/muL. In a multivariate analysis, the
treatment group did not affect the response of CD4(+) T cells; however, increased age, pretreatment
with nucleoside reverse-transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers
for Disease Control and Prevention stage C infection, lower baseline CD4(+) T cell count, and lower
baseline HIV-1 RNA level were risk factors for smaller increases in CD4(+) T cell count.
CONCLUSION: CD4(+) T cell recovery was similar in patients receiving nonboosted PI-, NNRTI-, and
boosted PI-based cART.
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Background. In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection
have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors
(NNRTIs) and boosted PI–based antiretroviral drug regimens, but the impact on immunological recovery remains
uncertain.
Methods. During January 1996 through May 2007, all patients in the Swiss HIV Cohort were included if they
received the first combination antiretroviral therapy (cART) and had known baseline CD4+ T cell counts and HIV-
1 RNA values ( ). The mean (SD) duration of follow-up was months. The follow-up timenp 3293 26.8 20.5
was limited to the duration of the first cART. CD4+ T cell recovery was analyzed in 3 different treatment groups:
nonboosted PI, NNRTI, or boosted PI. The end point was the absolute increase of CD4+ T cell count in the 3
treatment groups after the initiation of cART.
Results. Two thousand five hundred ninety individuals (78.7%) initiated a nonboosted-PI regimen, 452 (13.7%)
initiated an NNRTI regimen, and 251 (7.6%) initiated a boosted-PI regimen. Absolute CD4+ T cell count increases
at 48 months were as follows: in the nonboosted-PI group, from 210 to 520 cells/mL; in the NNRTI group, from
220 to 475 cells/mL; and in the boosted-PI group, from 168 to 511 cells/mL. In a multivariate analysis, the treatment
group did not affect the response of CD4+ T cells; however, increased age, pretreatment with nucleoside reverse-
transcriptase inhibitors, serological tests positive for hepatitis C virus, Centers for Disease Control and Prevention
stage C infection, lower baseline CD4+ T cell count, and lower baseline HIV-1 RNA level were risk factors for
smaller increases in CD4+ T cell count.
Conclusion. CD4+ T cell recovery was similar in patients receiving nonboosted PI–, NNRTI-, and boosted PI–
based cART.
The major aim of combination antiretroviral therapy
(cART) is the reduction of HIV-1–related morbidity
and mortality by suppression of plasma HIV-1 RNA,
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with a subsequent increase in CD4+ T cell count [1–
4]. The CD4+ T cell level reached during the first 5
years of cART strongly depends on baseline CD4+ T
cell count, even among patients with completely sup-
pressed plasma HIV-1 RNA [5, 6]. Other factors that
have been shown to result in a better CD4+ T cell re-
covery are the absence of prior antiretroviral therapy
(ART), lower baseline CD8+ T cell count, younger age,
and cART that does not contain zidovudine (ZDV) [5,
7–9].
Several antiretroviral drugs have become available in
the past few years, and strategies for treatment of HIV
infection have changed [10–14]. The frequent dosing
schedule, the high pill burden, and adverse events have
led to a preference for a once-daily antiretroviral drug
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Table 1. Baseline demographic characteristics by combination antiretroviral therapy (cART) regimen.
Variable
All patients
(n p 3293)
Nonboosted-PI
cART
(n p 2590)
NNRTI-containing
cART
(n p 452)
Boosted-PI
cART
(n p 251)
Sex
Male 2367 (71.9) 1862 (71.9) 320 (70.8) 185 (73.7)
Female 926 (28.1) 728 (28.1) 132 (29.2) 66 (26.3)
Age, mean years  SD 38.2  9.5 37.9  9.2 38.5  10.4 40.7  10.0
Ethnicity
White 2748 (83.4) 2179 (84.1) 356 (78.8) 213 (84.9)
Black 278 (8.4) 193 (7.5) 68 (15.0) 17 (6.8)
Hispanic 56 (1.7) 39 (1.5) 11 (2.4) 6 (2.4)
Asian 78 (2.4) 54 (2.1) 12 (2.7) 12 (4.8)
Other/no information 133 (4.0) 125 (4.8) 5 (1.1) 3 (1.2)
HIV transmission category
MSM 1167 (35.4) 923 (35.6) 163 (36.1) 81 (32.3)
Heterosexual intercourse 1109 (33.7) 815 (31.5) 187 (41.4) 107 (42.6)
IDU 883 (26.8) 756 (29.2) 81 (17.9) 46 (18.3)
Other/unknown 134 (4.1) 96 (3.7) 21 (4.6) 17 (6.8)
Duration of HIV-1 infection, mean years  SD 5.4  4.6 5.6  4.4 4.7  5.3 4.6  5.6
CDC infection stage
A 1480 (46.0) 1153 (44.5) 237 (52.4) 90 (35.9)
B 998 (31.0) 819 (31.6) 120 (26.5) 59 (23.5)
C 737 (22.9) 608 (23.5) 67 (14.8) 62 (24.7)
Unknown 78 (2.4) 10 (0.4) 28 (6.2) 40 (15.9)
Pretreated 1351 (41.0) 1262 (48.7) 57 (12.6) 32 (12.7)
Baseline HIV-1 RNA level, median log10 copies/mL (IQR) 4.8 (4.2–5.3) 4.7 (4.1–5.3) 4.9 (4.5–5.4) 5.3 (4.8–5.7)
Baseline CD4+ T cell count, median cells/mL (IQR) 201 (88–340) 201 (86–345) 220 (130–331) 168 (50–288)
Baseline CD8+ T cell count, median cells/mL (IQR) 733 (474–1090) 724 (467–1069) 803 (519–1215) 710 (445–1097)
Positive for HCV antibody 1052 (33.0) 903 (34.9) 95 (21.0) 54 (21.5)
Unknown 102 (3.1) 23 (0.9) 37 (8.2) 42 (16.7)
ZDV treatment 1792 (54.4) 1232 (47.6) 362 (80.1) 198 (78.9)
NOTE. Data are no. (%) of patients, unless otherwise indicated. CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus; IDU, injection
drug use; IQR, interquartile range; MSM, men having sex with men; ZDV, zidovudine.
regimen consisting of 3 compounds, including a nonnucleoside
reverse-transcriptase inhibitor (NNRTI) or a boosted protease
inhibitor (PI) [15, 16]. However, direct comparisons of these
antiretroviral drug regimens, with respect to the long-term re-
covery of CD4+ T cell count, are scarce. Importantly, this is
particularly the case for follow-up studies that assess the first,
unchanged cART. This issue may be particularly important for
developing countries, where newer treatment options remain
unavailable. Four large studies comparing ART in treatment-
naive patients using either an NNRTI- or a PI-based cART for
a maximum follow-up of 32 months found comparable re-
sponses of CD4+ T cell count [17–20]. However, other studies
found smaller increases in CD4+ T cell count in individuals
using an NNRTI-based cART at 48 and 96 weeks [21–23]. In
the present study, we analyzed the long-term CD4+ T cell re-
covery in 3293 patients of the Swiss HIV Cohort Study (SHCS)
who received the first cART that included a nonboosted PI,
NNRTI, or a boosted PI.
PATIENTS AND METHODS
Study participants. All patients of the SHCS who initiated
their first cART during January 1996 through May 2007 were
analyzed. The SHCS is a prospective, observational study of
HIV-1–infected adults that was initiated in 1988, with clinical
and laboratory follow-up documented every 6 months. En-
rollment is independent of disease stage and treatment [24, 25].
cART was defined as a drug regimen containing a nucleoside
reverse-transcriptase inhibitor (NRTI) backbone with a PI,
NNRTI, or a ritonavir-boosted PI. Patients who had received
prior treatment with NRTIs were also included. Laboratory
values, including CD4+ and CD8+ T cell count and plasma HIV-
1 RNA level, were monitored at 3–6-month intervals.
All patients with unknown baseline CD4+ T cell counts (1295
patients) or unknown plasma HIV-1 RNA values (195 patients)
were excluded. In addition, all patients whose first cART du-
ration was !3 months were excluded (790 patients).
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Figure 1. Absolute CD4+ T cell counts (A) and percentages (B) by
treatment regimen. ART, antiretroviral therapy; NNRTI, nonnucleoside re-
verse-transcriptase inhibitor; PI, protease inhibitor.
Study design. CD4+ T cell count increases were analyzed
during the first cART until ART was stopped or switched to
another cART regimen. The mean (SD) follow-up was
months. The reasons for discontinuation of ART26.8 20.5
could not be analyzed in detail, because these data were not
collected for the SHCS database during the entire analyzed
period. Treatment discontinuation was classified as virological
failure if the prior 2 plasma HIV-1 RNA measurements were
1400 copies/mL.
CD4+ T cell count increase was compared in 3 groups by
type of ART. Group 1 consisted of patients receiving non-
boosted PI–based drug regimens (2590 patients [78.7%]).
These individuals commenced a drug regimen with indinavir
(953 patients), ritonavir (357 patients), nelfinavir (992 pa-
tients), saquinavir (109 patients), and at least 2 NRTIs or a
triple combination with saquinavir, ritonavir, and 1 NRTI (179
patients). Of the 2590 patients in this group, 2327 (89.8%) had
been receiving treatment at 6 months, 1794 (69.3%) had been
receiving treatment at 12 months, 1103 (42.6%) had been re-
ceiving treatment at 24 months, 718 (27.7%) had been receiving
treatment at 36 months, and 457 (17.6%) had been receiving
treatment at 48 months.
Group 2 (452 [13.7%] of 3293 patients) received an NNRTI
in combination with at least 2 NRTIs. Most patients received
efavirenz (420 patients), and a small proportion of patients
received nevirapine (32 patients). Of 452 patients treated with
an NNRTI-containing regimen, 425 (94.0%) had been receiving
treatment at 6 months, 351 (77.7%) had been receiving treat-
ment at 12 months, 250 (55.3%) had been receiving treatment
at 24 months, 187 (41.4%) had been receiving treatment at 36
months, and 108 (23.9%) had been receiving treatment at 48
months.
The third group received boosted PIs in combination with
at least 2 NRTIs (251 [7.6%] of the 3293 patients). These pa-
tients received 100 mg ritonavir in combination with lopinavir
(160 patients), saquinavir (29 patients), indinavir (60 patients),
or atazanavir (2 patients). Of these 251 patients, 218 (86.9%)
had been receiving treatment at 6 months, 165 (65.7%) had
been receiving treatment at 12 months, 98 (39.0%) had been
receiving treatment at 24 months, 55 (21.9%) had been re-
ceiving treatment at 36 months, and 28 (11.2%) had been
receiving treatment at 48 months. cART containing nonboosted
PI was more common during 1996–2000. cART containing
NNRTIs and boosted PIs was more common after 2000.
Statistical analysis. The primary end point of the study
was the absolute increase in CD4+ T cell count from baseline
in the 3 different treatment groups. Absolute increases of CD4+
T lymphocyte count were analyzed using a Cox proportional
hazards model. The potential factors for CD4+ T lymphocyte
recovery were evaluated as follows: sex, age, duration of HIV-
1 infection, pretreatment with NRTIs, Centers for Disease Con-
trol and Prevention (CDC) stage C infection, hepatitis C virus
(HCV) coinfection, baseline HIV-1 RNA level, baseline CD4+
and CD8+ T cell counts, inclusion of ZDV in the antiretroviral
drug regimen, year of initiation of cART, and the 3 groups of
ART.
A 2-sided P value !.05 was considered to be statistically
significant. All statistical analyses were performed with SPSS,
version 14.0 (SPSS).
RESULTS
Patient characteristics. In total, 3293 individuals were in-
cluded in the analysis, of whom 2367 (71.9%) were men. The
mean age (SD) was years. The percentage of in-38.2 9.5
jection drug users was smaller in the NNRTI group and the
boosted-PI group than in the nonboosted-PI group (17.9% and
18.3% vs. 29.2%; and , respectively). In ad-P ! .001 Pp .001
dition, the proportion of untreated individuals was higher
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Table 2. Determinants of patient CD4+ T cell count changes.
Variable
Unadjusted analysis Adjusted analysis
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Female sex 1.14 (1.00–1.28) .043 1.07 (0.94–1.22) .304
Agea 0.83 (0.78–0.89) !.001 0.84 (0.79–0.90) !.001
Duration of HIV-1 infectionb 0.96 (0.95–0.98) !.001 1.00 (0.98–1.01) .698
Treatment experienced 0.61 (0.54–0.69) !.001 0.69 (0.61–0.79) !.001
Positive for HCV antibody 0.79 (0.69–0.89) !.001 0.79 (0.69–0.89) !.001
CDC stage C infection 0.68 (0.59–0.79) !.001 0.81 (0.69–0.95) .009
Baseline HIV-1 RNA levelc 1.14 (1.07–1.22) !.001 1.21 (1.12–1.30) !.001
Baseline CD4+ T cell countd 1.10 (1.08–1.13) !.001 1.13 (1.10–1.16) !.001
Baseline CD8+ T cell countd 1.00 (0.99–1.01) .587 0.98 (0.97–0.99) !.001
ZDV therapy 0.97 (0.87–1.09) .597 0.85 (0.76–0.96) .008
Year of cARTb 1.05 (1.03–1.08) !.001 1.00 (0.97–1.04) .853
Nonboosted-PI versus NNRTI-containing regimen 1.16 (0.99–1.35) .061 0.97 (0.82–1.15) .709
Nonboosted PI versus boosted PI 1.26 (1.03–1.54) .027 1.06 (0.84–1.33) .648
NOTE. CD4+ T cell increases were 1300 cells/mL. A Cox proportional hazards model was used for this analysis. cART, combination
antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus; NNRTI, nonnucleoside reverse-tran-
scriptase inhibitor; PI, protease inhibitor; ZDV, zidovudine.
a Per 10-year increase.
b Per 1-year increase.
c Per 1-log plasma HIV-1 RNA level increase.
d Per 100-cell increase.
(87.4% and 87.3% vs. 51.3%; for both comparisons),P ! .001
and the duration of HIV-1 infection was shorter (4.7 and 4.6
vs. 5.6 years; for both comparisons). In the NNRTI-P ! .001
containing cART group, fewer patients had CDC stage C in-
fection (14.8% vs. 23.5%; ). On the other hand, medianP ! .001
baseline CD4+ T cell count was lower in the boosted-PI cART
group than in the nonboosted-PI cART group (168 vs. 201
cells/mL; ), probably reflecting the tendency of phy-Pp .002
sicians to start treatment with a double PI–containing regimen
in patients with low CD4+ T cell counts. In the nonboosted-
PI group, 34.9% of patients had a positive HCV antibody test
result, whereas those percentages were statistically significantly
lower in the other 2 groups (21.0% and 21.5%; andP ! .001
, respectively). Patients who received treatment withPp .006
a nonboosted PI–containing cART had a statistically signifi-
cantly lower proportion of individuals receiving ZDV. Further
baseline characteristics are shown in table 1.
Response of CD4+ T lymphocytes to cART. In the non-
boosted-PI group, CD4+ T lymphocytes increased from a me-
dian of 210 cells/mL (interquartile range [IQR], 86–370 cells/
mL) to 520 cells/mL (IQR, 350–717 cells/mL) at 48 months,
whereas similar increases of CD4+ T lymphocytes were observed
in the NNRTI group (220 cells/mL [IQR, 130–331 cells/mL] to
475 cells/mL [IQR, 362–668 cells/mL]) and in the boosted-PI
group (168 cells/mL [IQR, 50–288 cells/mL] to 511 cells/mL
[IQR, 412–767 cells/mL]) at 48 months. The increase in CD4+
T cell count of the 3 groups was not statistically significantly
different ( ) (figure 1A).P 1 .01
In a multivariate analysis, patients who achieved an increase
over the threshold of 300 CD4+ T cells/mL were investigated.
In this analysis, adjusted for confounding variables, higher age,
previous NRTI treatment, a test result positive for HCV anti-
body, CDC stage C infection, and therapy with ZDV showed
a statistically significantly smaller increase of CD4+ T lympho-
cytes, whereas a higher baseline CD4+ T cell count and higher
baseline HIV-1 RNA value resulted in a better recovery of these
cells. However, the antiretroviral treatment regimen did not
statistically significantly affect absolute increases in the CD4+
T cell count (table 2).
The changes of CD4+ T cell percentages were similar in all
3 groups. In the nonboosted group, median percentages in-
creased from 15% (IQR, 8–23 cells/mL) to 28% (IQR, 21–34
cells/mL) at 48 months; in the NNRTI group, percentages in-
creased from 15% (IQR, 10–21.75 cells/mL) to 29% (IQR, 22–
35 cells/mL); and in the boosted group, percentages increased
from 12% (IQR, 6–18 cells/mL) to 29% (IQR, 23–36 cells/mL)
(figure 1B).
Virological response. Patients with nonboosted cART ini-
tiated ART at a median plasma HIV-1 RNA value of 4.75 log10
copies/mL. Individuals who received NNRTI initiated cART at
a slightly higher value, 4.94 log10 copies/mL ( ), whereasP ! .001
patients who received boosted cART commenced ART at the
highest HIV-1 RNA value, 5.26 log10 copies/mL ( ) (fig-P ! .001
ure 2A). A statistically significant decrease in the HIV-1 RNA
level was achieved in all treatment groups after 6 months. In
the NNRTI treatment group and in the boosted cART group,
HIV-1 RNA level decreased statistically significantly faster than
in the nonboosted cART group ( ). Median HIV-1 RNAP ! .001
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Figure 2. A, HIV-1 RNA levels by treatment regimen. B, Percentages
of patients with HIV-1 RNA levels 1400 copies/mL, by treatment regimen.
ART, antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase
inhibitor; PI, protease inhibitor.
Figure 3. Increase of absolute CD4+ T cell counts from baseline for
all patients by undetectable HIV-1 RNA level (400 copies/mL; 2159
patients) and detectable HIV-1 RNA level (1400 copies/mL; 1134 patients)
over 48 months.
level at 6 months was 2.36 log10 copies/mL (IQR, 1.49–3.19
copies/mL) in the nonboosted group, 1.74 log10 copies/mL
(IQR, 1.01–2.50 copies/mL) in the NNRTI group, and 1.54
log10 copies/mL (IQR, 1.05–2.08 copies/mL) in the boosted
group.
The proportion of HIV-1 RNA values !400 copies/mL was
initially higher in the NNRTI-containing group and in the
boosted-PI group, but the proportion remained only slightly
higher in the NNRTI group ( ) (figure 2B).Pp .04
At discontinuation of first cART, 28.7% of the nonboosted-
PI group experienced virological failure, whereas virological
failure was observed less frequently in the other 2 groups
(NNRTI group, 11.1%; boosted-PI group, 10.0%).
CD4+ T cell increases in patients with HIV-1 RNA levels
!400 copies/mL. After 6 months of treatment, 2159 patients
(65.6%) had undetectable HIV-1 RNA values (i.e., !400 copies/
mL), and viral load remained suppressed for the entire obser-
vation period. The increase of median absolute CD4+ T cell
count of these patients was statistically significantly higher than
those of patients with 1 plasma HIV-1 RNA test result 1400
copies/mL after 6 months (322 cells/mL [IQR, 218–462 cells/
mL] vs. 212 cells/mL [IQR, 103–413 cells/mL]; ) (fig-P ! .001
ure 3).
In the group that received nonboosted treatment, median
absolute CD4+ T cell counts increased from 224 cells/mL (IQR,
100–372 cells/mL) to 546 cells/mL (IQR, 388–750 cells/mL) in
patients with all HIV-1 RNA values !400 copies/mL after 6
months, whereas these cell counts increased in patients with at
least 1 test showing an HIV-1 RNA level 1400 copies/mL after
6 months, from 167 cells/mL (IQR, 70–290 cells/mL) to 491
cells/mL (IQR, 336–648 cells/mL; ).Pp .017
In the group receiving NNRTI-containing treatment, a sim-
ilar pattern was observed. The CD4+ T lymphocyte count in-
creased from a median of 218 cells/mL (IQR, 131–327 cells/mL)
to 492 cells/mL (IQR, 338–711 cells/mL; ) in patientsPp .328
with all HIV-1 RNA values !400 copies/mL after 6 months,
whereas in patients with 1 HIV-1 RNA value 1400 copies/
mL, these cell counts increased only from 243 cells/mL (IQR,
122–370 cells/mL) to 361 cells/mL (IQR, 288–414 cells/mL;
).Pp .062
In the group that received boosted-PI treatment, CD4+ T
lymphocyte counts increased from 170 cells/mL (IQR, 52–288
cells/mL) to 563 cells/mL (IQR, 425–973 cells/mL; ) inPp .162
patients with all HIV-1 RNA test results !400 copies/mL after
6 months, whereas in patients with1 HIV-1 RNA value 1400
copies/mL, these cell counts increased from 139 cells/mL (IQR,
46–245 cells/mL) to 460 cells/mL (IQR, 180–512 cells/mL; Pp
)..199
CD4+ T cell increases according to baseline CD4+ T cell count.
CD4+ T cell count was stratified into 3 groups according to
baseline CD4+ T cell count: 0–149 cells/mL, 150–299 cells/mL, and
1098 • CID 2008:47 (15 October) • HIV/AIDS
Figure 4. Absolute CD4+ T cell count with baseline CD4+ T cell count
of 0–149 cells/mL (A), 150–299 cells/mL (B), and 300 cells/mL (C) by
treatment regimen. ART, antiretroviral therapy; NNRTI, nonnucleoside re-
verse-transcriptase inhibitor.
300 cells/mL. The increase in CD4+ T cell count was similar in
all strata in all 3 treatment groups (figure 4A–4C).
CD4+ T cell increases, excluding patients pretreated with
nucleosides. In a subanalysis, all patients who were pretreated
with NRTIs were excluded ( ). In a multivariate anal-np 1351
ysis, the CD4+ T cell count in the boosted-PI group was slightly
higher than that in the nonboosted-PI group (median, 568 cells/
mL [IQR, 431–973 cells/mL] vs. 547 cells/mL [IQR, 396–740 cells/
mL; ). A boosted-PI regimen may, therefore, result inPp .03
slightly better CD4+ T cell responses in treatment-naive pa-
tients, compared with patients who had received previous treat-
ment. However, the number of patients with a follow-up of 48
months was very small (9 patients). The boosted-PI group was,
therefore, not analyzed at all, and the results presented here
should be interpreted with caution.
CD4+ T cell increases in patients receiving ZDV. We ob-
served a trend toward a larger increase in CD4+ T cell count
among patients who did not receive ZDV than among indi-
viduals who did receive ZDV as a component of the drug
regimen. The median CD4+ T cell count increased from 206
cells/mL (IQR, 83–349 cells/mL) to 544 cells/mL (IQR, 382–734
cells/mL) in the ZDV-naive group and from 200 cells/mL (IQR,
93–335 cells/mL) to 494 cells/mL (IQR, 363–689 cells/mL) in the
ZDV-treated group. In the multivariate model, the difference
in CD4+ T cell increase reached statistical significance (Pp
) (table 2)..008
Response of CD8+ T lymphocytes to cART. The changes in
CD8+ T lymphocytes showed a similar pattern in the 3 groups.
In the nonboosted-PI group, median absolute CD8+ T cell
counts increased from 724 cells/mL (range, 467–1069 cells/mL)
to 843 cells/mL (range, 633–1171 cells/mL); in the NNRTI-
group, counts increased from 803 cells/mL (range, 519–1215
cells/mL) to 809 cells/mL (range, 612–1033 cells/mL; );Pp .141
and in the boosted group, counts increased from 710 cells/mL
(range, 445–1097 cells/mL) to 747 cells/mL (range, 621–1003
cells/mL; ). The median CD8+ T cell percentages in-Pp .319
creased to comparable values in all 3 groups ( ).P 1 .05
DISCUSSION
In this study, we compared the impact of 3 major strategies of
ART on CD4+ T cell recovery for first unchanged cART in a
large number of participants of the SHCS. In the first years of
cART, patients received a nonboosted-PI regimen or an NNRTI
in combination with NRTIs. More recently, ritonavir-boosted
PI-containing regimens were applied as well. The main finding
of this study suggests that all 3 treatment strategies result in a
similar recovery of CD4+ T cells.
In other studies, the comparison of NNRTI-containing reg-
imens and PI-based regimens, with regard to CD4+ T cell re-
covery, had contradictory results. In the Atlantic Study, a non-
boosted-PI regimen with indinavir resulted in a larger increase
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in the CD4+ T cell count than did an ART that was based on
nevirapine and 2 nucleoside analogues [21]. This finding was
also supported by a meta-analysis that found an improvement
of the virological response, immunological recovery, and a re-
duced progression to AIDS or death among patients receiving
PIs [26]. However, a limiting factor of the meta-analysis was
the large number of NRTI-pretreated patients, whose treatment
might have induced NNRTI resistance. In contrast, an addi-
tional meta-analysis including only treatment-naive patients
demonstrated a better immunological and virological outcome
of NNRTI-based regimens, without any influence on clinical
outcomes [27]. Several other studies, including ours, did not
find any difference in the immunological recovery between
patients who received nonboosted-PI and NNRTI treatment
[18, 19, 28].
Only a few studies, which investigated immunological re-
covery, compared boosted PI–based regimens with NNRTI-
containing regimens. In one study, an efavirenz-based regimen
was compared with a lopinavir-ritonavir–containing regimen.
No difference in CD4+ T cell count recovery was found, in-
cluding among patients with low baseline CD4+ T cell levels
[29]. In another randomized, double-blind, controlled trial in-
volving treatment-naive patients, results of a once-daily ata-
zanavir-containing therapy were compared with those of an
efavirenz-based regimen over 48 weeks [30]. The study found
a comparable virological response and CD4+ T cell count in-
crease [30]. Nevertheless, this contrasts a recently published
study that compared results of lopinavir-ritonavir plus 2 NRTIs,
efavirenz plus 2 NRTIs, and lopinavir-ritonavir plus efavirenz
in 753 treatment-naive patients over 96 weeks [31]. In that
study, the 2 PI-based therapies resulted in statistically signifi-
cantly higher CD4+ T cell count increases than did the efavi-
renz-based treatment. However, the time to virological failure
was significantly shorter in the lopinavir-ritonavir group [31].
Studies comparing results of nonboosted and boosted PI–
based regimens are scarce. In one study, no difference in CD4+
T cell count increase could be demonstrated in comparison of
lopinavir-ritonavir with nelfinavir at 1-year follow-up [32]. Our
study showed similar CD4+ T cell count increases in the 2
treatment groups. Because of the significant imbalance of the
number of patients, especially those in the nonboosted-PI
group who had received prior ART, a subanalysis was performed
that either excluded all pretreated individuals or used a similar
number of randomly chosen patients for each treatment group.
If pretreated patients were excluded, a slightly better CD4+ T
cell increase was found among patients in the boosted-PI group.
However, the reduction of the number of observations in the
nonboosted-PI group had no impact on the results.
In the present study, 3 major groups of antiretroviral thera-
peutic regimens were analyzed, but the effect of individual com-
pounds was not assessed in detail. Therefore, we cannot exclude
the possibility that individual drugs had a slightly better effect
on CD4+ T cell recovery than did others. Because of the ex-
tended number of possible antiretroviral combinations and the
limited number of long-term observations on 1 specific treat-
ment, a more detailed analysis was not performed. However,
we did not find an indication that major antiretroviral drug
regimens including indinavir, efavirenz, or lopinavir-ritonavir
would show different CD4+ T cell count responses.
A total of 24.8% of all patients who discontinued cART had
2 test results indicating a plasma HIV-1 RNA level 1400 copies/
mL. The percentage was higher in the nonboosted-PI group
than in the 2 other groups (28.7% vs. 11.1% and 10.0%). This
observation may indicate that many patients in the nonboosted-
PI group were pretreated and were therefore more likely to
experience ART failure.
We confirmed the findings of previous studies that patients
with undetectable HIV-1 RNA level, younger age, and higher
CD4+ T cell count at baseline enhance CD4+ T cell recovery [5,
7, 8, 33]. In particular, many patients with CD4+ T cell counts
!300 cells/mL did not achieve CD4+ T cell counts 1500 cells/mL.
Therefore, to achieve good immunological recovery, cART should
not be deferred until late stages of HIV-1 infection. We showed
additional and less common factors influencing CD4+ T cell
recovery. In the multivariate analysis, a positive HCV status,
usually the case for injection drug users, limited the recovery of
CD4+ T cell count. An impaired CD4+ T cell increase in HCV
seropositive patients over 36 months, including those with well-
suppressed HIV-1 RNA level, was reported elsewhere for the
SHCS [34]. Whether coinfection with HCV or a poorer adher-
ence to ART in this group of primarily injection drug users is
responsible for this observation remains to be shown. Lastly, we
confirmed previously published data that treatment with ZDV
hinders CD4+ T cell recovery [9].
Limitations of the study are inherent to all observational
cohort studies in which patients are not randomized. Therefore,
different numbers of patients were observed in each treatment
group, and there was an especially higher number in the non-
boosted-PI group. Moreover, patients received treatment for a
different amount of time; therefore, confounding data cannot
be excluded.
In summary, the increase in the CD4+ T cell count was similar
among recipients of nonboosted PI– and NNRTI- and rito-
navir-boosted PI–based regimens. However, treatment-naive
patients showed a statistically significantly better CD4+ T cell
recovery if they were in early CDC infection stages, were young,
were HCV negative, and had not received ZDV.
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